Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others. A study published in Nature Communications, by a multidisciplinary team ...
Influence of body composition on the efficacy of chemotherapy in men with metastatic aggressive variant prostate cancer (AVPC). Overall survival in men with metastatic castration-resistant prostate ...
*Likely reflects later-line therapy and selection for biomarker-positive advanced disease. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium. This abstract does not ...
Sony is reportedly making another Venom movie. This time, it’s going to be animated. How closely the surprise animated project will stick to the events of the recent trilogy starring Tom Hardy, with ...
Chong Kun Dang Pharmaceutical Corp. has synthesized poly (ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors designed for use in the treatment of cancer and inflammatory disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results